Prognosis of Hepatocellular Carcinoma in Relation to Treatment Across BCLC Stages

• Published in: Annals of surgical oncology 2011-07, Vol.18 (7), p.1964-1971
• Main Authors: D’Avola, Delia, Iñarrairaegui, Mercedes, Pardo, Fernando, Rotellar, Fernando, Marti, Pablo, Bilbao, José I., Martinez-Cuesta, Antonio, Benito, Alberto, Alegre, Felix, Mauleón, Erica, Herrero, José I., Quiroga, Jorge, Prieto, Jesus, Sangro, Bruno
• Format: Article
• Language: English
• Subjects: Aged; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - therapy; Catheter Ablation; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Hepatobiliary Tumors; Humans; Liver Neoplasms - pathology; Liver Neoplasms - therapy; Liver Transplantation; Male; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - therapy; Neoplasm Staging; Oncology; Prognosis; Retrospective Studies; Surgery; Surgical Oncology; Survival Rate
• ISSN: 1068-9265; 1534-4681
• DOI: 10.1245/s10434-011-1551-4

Background The Barcelona Clinic Liver Cancer (BCLC) staging system recommends first-line therapy for each tumor stage. We evaluated the effect of compliance with BCLC treatment allocation on the prognosis of patients with hepatocellular carcinoma (HCC). Methods We retrospectively analyzed 359 consecutive, newly diagnosed HCC patients treated in our Liver Unit during a 14-year period. For each stage, survival was compared according to whether treatment matched the BCLC recommendation. We also compared the survival of patients in the same BCLC stage who received different treatments, and patients in different BCLC stages receiving the same treatment. Results BCLC-A patients treated with radical therapies (66%) survived longer (117 vs. 20 months; p